RxDoctor Payments Data

Pramod Kadambi, MD

Cardiology · Lancaster, CANPI 1114988441

Payments from drug & device makers

What this record shows

16 manufacturers reported payments, led by Edwards Lifesciences at 51.6% of the total. 2025 is the largest year on record at $2,318, more than ten times the $125 reported in 2019.

$6,627in general payments, 2019–2025

Across 98 payments — averaging $67.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$3K
  • Boston Scientific$1K
  • Abbott$946
  • Medtronic$348
  • Abiomed$304
  • Amgen$142
  • plus $307 from 10 others

What the payments were for

  • Travel & lodging$3,52053%
  • Food & beverage$3,10747%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,627 in reported general payments places this provider in the 85th percentile of 156 cardiology providers in California.

See all cardiology providers in California

Medicare billing

Part B allowed, 2024
$575,862
Medicare patients
1,064
Services billed
3,900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban163$172,148
EntrestoSacubitril/Valsartan58$66,409
XareltoRivaroxaban47$57,830
Repatha SureclickEvolocumab59$39,657
Repatha SyringeEvolocumab15$20,491
FarxigaDapagliflozin Propanediol14$18,117
JardianceEmpagliflozin11$17,754
Metoprolol Succinate253$3,609
Atorvastatin Calcium348$3,412
Ezetimibe42$2,540
Valsartan85$2,514
Amiodarone Hcl107$1,706
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide50$1,613
Amlodipine Besylate253$1,459
Rosuvastatin Calcium96$1,447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$21$18,11714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 156 cardiology providers in California.

Other cardiology in Lancaster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →